Project Number: 6040-32000-062-04-T
Project Type: Trust Fund Cooperative Agreement
Start Date: Apr 1, 2013
End Date: Mar 29, 2015
1. To evaluate protection from low pathogenic avian influenza (AI) using a novel recombinant Bacillus vaccine expressing epitopes from the AI HA, NP and M2e proteins. 2. To characterize the serologic response following challenge.
A Bacillus-vectored vaccine expressing epitopes from the AI HA, NP and M2e proteins will be generated by PGT (Pacific GeneTech Limited, Hong Kong). Groups of 8-10, one-day-old commercial chickens will be injected with inactivated bacillus-AI vaccine. After 21 days, the birds will be transported to SEPRL for challenge with LPAI H7N2 under BSL3Ag conditions. Protective immunity will be evaluated by morbidity /mortality to challenge, with oral and cloacal swabs taken to determine viral shedding. Humoral immunity will be evaluated by ELISA and/or HI.